Trial Profile
Exploratory pathophysiological study in five patients suffering from new-onset lupus nephritis and treated with rituximab as first-line treatment
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 24 May 2019
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Lupus nephritis
- Focus Pharmacodynamics
- Acronyms NL_RTX_FIRST
- 24 May 2019 Status changed from recruiting to discontinued.
- 14 Aug 2017 New trial record